

17 June 2026
EMA/141831/2026
Public Health Threats (HT)

Agenda for ETF-stakeholders meeting on biodistribution of mRNA vaccines

26 June 2026 @ 14:00 CET time – hybrid (Teams and Room 0A)

Background

EMA's emergency task force (ETF) is organising a meeting with academic experts and industry stakeholders to strengthen current knowledge and foster further research on the biodistribution of mRNA vaccines components (i.e. the mRNA molecules and the produced antigen).

The meeting will be an opportunity to discuss which additional research could be conducted in humans to complement the available nonclinical data on the biodistribution of mRNA products. Such work may also help address scientific questions, take stock of current methodologies and stimulate discussion on potential research areas.

Chair: Marco Cavaleri, head of Public Health Threats Department & co-Chair of the Emergency Task Force (ETF)

Order	Topics	Speaker	Time and special attendance
1	<i>Teleconference opening</i> Welcome and short introduction		

Order	Topics	Speaker	Time and special attendance
2	MAHs perspective on addressing the biodistribution of mRNA vaccines in humans	Industry stakeholders by Vaccines Europe	45'
3	Persistence of COVID-19 mRNA vaccines in vaccinated patients	James Stone, Harvard Medical School	20'
4	Persistence of mRNA vaccine in lymph nodes	Scott Boyd, Stanford University	20'
5	Monitoring mRNA vaccine antigen expression in vivo using PET/CT	Mohamad-Gabriel Alameh, University of Pennsylvania	25'
6	Fine needle aspiration of lymph nodes	Shane Crotty, La Jolla Institute for Immunology	20'
7	Brainstorming with key experts on possible study design and research agenda	All participants	45'
	<i>Teleconference closing</i>		